MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Vertex Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

484.44 -0.01

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

480.95

Max

490.82

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-132M

913M

Pardavimai

142M

2.9B

P/E

Sektoriaus vid.

30.42

63.778

Pelnas, tenkantis vienai akcijai

3.98

Pelno marža

31.353

Darbuotojai

6,100

EBITDA

-99M

1.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+2.94% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

6.8B

127B

Ankstesnė atidarymo kaina

484.45

Ankstesnė uždarymo kaina

484.44

Naujienos nuotaikos

By Acuity

35%

65%

113 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-10 22:11; UTC

Uždarbis

Vertex Pharmaceuticals Posts Higher 4Q Revenue

2025-01-31 00:19; UTC

Pagrindinės rinkos jėgos

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

2024-12-19 12:25; UTC

Pagrindinės rinkos jėgos

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

2024-11-04 21:44; UTC

Uždarbis

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

2024-08-01 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-11 21:12; UTC

Uždarbis

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

2025-02-11 14:21; UTC

Uždarbis

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

2025-02-10 21:12; UTC

Uždarbis

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

2025-02-10 21:12; UTC

Uždarbis

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

2025-02-10 21:11; UTC

Uždarbis

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

2025-02-10 21:04; UTC

Uždarbis

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

2025-02-10 21:04; UTC

Uždarbis

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

2025-02-10 21:02; UTC

Uždarbis

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

2025-02-10 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

2025-02-10 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 4Q Net $913M >VRTX

2025-02-10 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

2025-02-10 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

2025-01-31 09:59; UTC

Karštos akcijos

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

2024-11-04 22:21; UTC

Uždarbis

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

2024-11-04 21:25; UTC

Uždarbis

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

2024-11-04 21:03; UTC

Uždarbis

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

2024-11-04 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

2024-11-04 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

2024-11-04 21:01; UTC

Uždarbis

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

2024-09-26 14:20; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

2024-08-01 20:30; UTC

Uždarbis

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

2024-08-01 20:03; UTC

Uždarbis

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

2024-08-01 20:02; UTC

Uždarbis

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

2024-08-01 20:02; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Akcijų palyginimas

Kainos pokytis

Vertex Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

2.94% į viršų

12 mėnesių prognozė

Vidutinis 499.09 USD  2.94%

Aukščiausias 591 USD

Žemiausias 320 USD

Remiantis 27 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vertex Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

27 ratings

16

Pirkti

10

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

471.5 / 505Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

113 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.